You are here

Personalized Medicine

Using sound waves, an international team of researchers has developed a gentle, contact-free method for separating circulating tumor cells from blood samples that is fast and efficient enough for clinical use.

Circulating tumor cells (CTCs) are small pieces of a tumor that break away and flow through the bloodstream. They contain a wealth of information about the tumor, such as its type, physical characteristics and genetic mutations.

Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.

Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.

Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps cancer cells proliferate and grow.

What is a microbiome and why are microbiomes unique to an individual?

A microbiome is the sum total of the microbes of bacteria, fungi, and viruses that live inside your body. They are all over your skin and in your gut. Bacteria alone accounts for 2-3 lbs of your body mass.

© vrx/Shutterstock.com

Each day, normal human cell tissues express a protein known as p53 that wages war against potential malignancies. However, between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53 that helps cancer cells proliferate and grow.

A new computational method developed by researchers at the New York Genome Center (NYGC) allows scientists to identify rare gene mutations in cancer cells with greater accuracy and sensitivity than currently available approaches.

The technique, reported in today's Communications Biology from Nature Research publishing, is called Lancet and represents a major advance in the identification of tumor cell mutations, a process known as somatic variant calling.

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.

Dr. Marjolaine Baldo, Commercial Vice President, EMEA at Agendia said:

A new computational method developed by researchers at the New York Genome Center (NYGC) allows scientists to identify rare gene mutations in cancer cells with greater accuracy and sensitivity than currently available approaches.

The technique, reported in today's Communications Biology from Nature Research publishing, is called Lancet and represents a major advance in the identification of tumor cell mutations, a process known as somatic variant calling.

Royal Philips, a global leader in health technology, today announced the launch of its Xplore web-based informatics platform for drug research and biomarker discovery. Part of Philips’ computational pathology portfolio, the new release marks a major upgrade for both pharma and academic researchers, as it will provide them with enhanced search capabilities, barcode support, data visualization tools and third party image analysis vendor integration.

 

Subscribe to Personalized Medicine